CL2018002523A1 - Profármacos del modulador selectivo del receptor de la progesterona (msrp) (11.beta.,17.beta.)-17-hidroxi-11-[4- (metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona - Google Patents

Profármacos del modulador selectivo del receptor de la progesterona (msrp) (11.beta.,17.beta.)-17-hidroxi-11-[4- (metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona

Info

Publication number
CL2018002523A1
CL2018002523A1 CL2018002523A CL2018002523A CL2018002523A1 CL 2018002523 A1 CL2018002523 A1 CL 2018002523A1 CL 2018002523 A CL2018002523 A CL 2018002523A CL 2018002523 A CL2018002523 A CL 2018002523A CL 2018002523 A1 CL2018002523 A1 CL 2018002523A1
Authority
CL
Chile
Prior art keywords
beta
msrp
estra
dien
pentafluoroethyl
Prior art date
Application number
CL2018002523A
Other languages
English (en)
Inventor
Antje Rottmann
Horst Irlbacher
Hans-Christian Militzer
Andrea Wagenfeld
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2018002523A1 publication Critical patent/CL2018002523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

ESTA INVENCIÓN SE RELACIONA CON LOS MODULADORES SELECTIVOS DEL RECEPTOR DE LA PROGESTERONA (MSRP) EN FORMA DE PROFÁRMACO ASÍ COMO TAMBIÉN CON SU APLICACIÓN EN TERAPIA. (3A,11ß,17ß)-11-[4-(METILSULFONIL)FENIL]-17-(PENTAFLUOROETIL)ESTRA-4,9-DIEN-3,17- DIOL (COMPUESTO 1) ES UNO DE LOS PROFÁRMACOS DE LA INVENCIÓN.
CL2018002523A 2016-03-04 2018-09-04 Profármacos del modulador selectivo del receptor de la progesterona (msrp) (11.beta.,17.beta.)-17-hidroxi-11-[4- (metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona CL2018002523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16158598.9A EP3214092A1 (en) 2016-03-04 2016-03-04 Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Publications (1)

Publication Number Publication Date
CL2018002523A1 true CL2018002523A1 (es) 2018-12-21

Family

ID=55486547

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002523A CL2018002523A1 (es) 2016-03-04 2018-09-04 Profármacos del modulador selectivo del receptor de la progesterona (msrp) (11.beta.,17.beta.)-17-hidroxi-11-[4- (metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona

Country Status (16)

Country Link
US (1) US10894805B2 (es)
EP (2) EP3214092A1 (es)
JP (1) JP2019511486A (es)
KR (1) KR20180118135A (es)
CN (1) CN108779142A (es)
AU (1) AU2017226922A1 (es)
BR (1) BR112018067517A2 (es)
CA (1) CA3016369A1 (es)
CL (1) CL2018002523A1 (es)
CO (1) CO2018009264A2 (es)
CR (1) CR20180426A (es)
MA (1) MA43691A (es)
MX (1) MX2018010658A (es)
RU (1) RU2018134045A (es)
SG (1) SG11201806771RA (es)
WO (1) WO2017148977A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
EP3384913A1 (en) 2017-04-03 2018-10-10 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulators and stabilized estrogen level in patient

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
EP1068338A2 (en) * 1998-03-06 2001-01-17 Oxford Biomedica (UK) Limited Enhanced prodrug activation
CA2433776A1 (en) 2001-01-09 2002-09-06 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
JP2002233378A (ja) * 2001-02-07 2002-08-20 Nihon Nosan Kogyo Kk ヒト由来のチトクロムｐ４５０分子種を認識する抗体
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2448422A1 (en) 2009-07-02 2012-05-09 University College Cork, National University Of Irland Cork Method for the production of a gum base
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) * 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011088270A1 (de) * 2011-12-12 2013-06-13 Bayer Intellectual Property Gmbh (11ß ,17ß)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluorethyl)estra-4,9-dien-3-on zur Behandlung von Morbus Charcot Marie Toot
SI2983671T1 (sl) 2013-04-11 2020-06-30 Bayer Pharma Aktiengesellschaft Dozirna oblika antagonista receptorja progesterona
EP3417863A1 (en) * 2015-05-18 2018-12-26 Bayer Pharma Aktiengesellschaft Selective progesterone receptor modulator (sprm) for use in the treatment of heavy menstrual bleeding
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
JP7086395B2 (ja) 2016-03-04 2022-06-20 ヴァンダービルト ユニバーシティー 置換インドールＭｃｌ－１阻害剤

Also Published As

Publication number Publication date
US10894805B2 (en) 2021-01-19
MA43691A (fr) 2021-03-17
US20190367555A1 (en) 2019-12-05
SG11201806771RA (en) 2018-09-27
CN108779142A (zh) 2018-11-09
RU2018134045A (ru) 2020-04-06
CR20180426A (es) 2018-11-21
KR20180118135A (ko) 2018-10-30
CO2018009264A2 (es) 2018-09-20
EP3214092A1 (en) 2017-09-06
BR112018067517A2 (pt) 2019-01-02
WO2017148977A1 (en) 2017-09-08
EP3423466A1 (en) 2019-01-09
CA3016369A1 (en) 2017-09-08
AU2017226922A1 (en) 2018-08-23
JP2019511486A (ja) 2019-04-25
RU2018134045A3 (es) 2020-04-27
MX2018010658A (es) 2019-01-17

Similar Documents

Publication Publication Date Title
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
DK3583203T3 (da) Donorreparationstemplates multiplex-genomeditering
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
MX2018005129A (es) Agonistas del receptor de glucagon.
IL261502A (en) Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
UY36311A (es) Indazoles sustituidos con bencilo
DK3221333T3 (da) 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer
DK3221331T3 (da) 6-alkyl-7-hydroxy-4-en-3-on-steroider som mellemprodukter til fremstilling af steroide fxr-modulatorer
HK1244286A1 (zh) 作為製備類固醇FXR調節劑的中間體的6α-烷基-6，7-二酮類固醇
MX2017000182A (es) Compuestos de pirazol como moduladores de fshr y usos de los mismos.
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
CL2017000505A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).
EA201790881A1 (ru) 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CL2017000152A1 (es) Derivados de isoindolinona
PL3691503T3 (pl) Łopatka do pojemników do mieszania
DK3827036T3 (da) Sammensætning til strukturklæbstof
CL2018002523A1 (es) Profármacos del modulador selectivo del receptor de la progesterona (msrp) (11.beta.,17.beta.)-17-hidroxi-11-[4- (metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EP3277281A4 (en) Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CO2017010535A2 (es) Dispositivo para la distribución uniforme de lechadas